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Abstract
Background: This study aimed to assess the occurrence of coronary artery lesions (CAL) in patients with Kawasaki
disease (KD) according to serum C-reactive protein (CRP) levels.
Methods: This retrospective analysis was based on the nationwide survey of KD conducted in the Republic of
Korea between 2015 and 2017. We enrolled 9131 patients and defined low (< 3mg/dL) and high (≥3 mg/dL) CRP
groups. Demographic data, clinical characteristics, z-scores, and scores based on the Japanese criteria for CAL were
compared between the two groups. Logistic regression analysis was used to identify CAL risk factors.
Results: The low CRP group accounted for 23% of patients. The mean age at diagnosis was higher in high CRP
group compared to the low CRP group (34.4 ± 24.9 vs 31.7 ± 24.8 months, p < 0.001). Fever duration before
treatment was not significantly different between the two groups (5.1 ± 1.7 days vs. 5.2 ± 2.1 days; p = 0.206). A non-
response to intravenous immunoglobulin treatment was found in 1377 patients (20.1%) and 225 patients (11.7%) in
the high and low CRP groups, respectively (p < 0.001). CAL were found in 12.9 and 18.3% of the high and low CRP
patients, respectively (p < 0.001), based on z-scores; and in 9.9 and 12.5%, respectively (p = 0.001), based on the
Japanese criteria in the acute phase. The giant coronary artery aneurysm occurrence ratio was similar between
groups (p = 1.0).
Conclusions: CAL occurred in patients with both high and low CRP. Therefore, patients with KD should be carefully
monitored regardless of their CRP levels.
Keywords: Acute-phase reactants, Coronary aneurysm, Intravenous immunoglobulins, Mucocutaneous lymph node
syndrome, Risk factors
Background
Kawasaki disease (KD) is a systemic inflammatory vascu-
lar disease that results in coronary artery complications
in 25% of untreated patients [1]. This disease is reported
in high frequency, particularly in Northeast Asia, includ-
ing Korea, and occurs primarily in children under 5 years
of age [2]. Systemic inflammation in KD is reflected by
an elevation of serum C-reactive protein (CRP) levels, an
acute phase reactant. In general, high serum CRP levels
are expected in KD. Therefore, in patients presenting
with incomplete KD that does not fulfill the diagnostic
criteria, a CRP serum level > 3 mg/dL is used as a criter-
ion to confirm KD [1].
At the same time, this rise in serum CRP levels is also
used as an index to predict KD that is refractory to treat-
ment [3–5]. Since the main purpose of KD treatment is
to minimize the occurrence of coronary artery complica-
tions through appropriate treatment, patients with high
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CRP, which are expected to be less responsive to treat-
ment, are treated with caution. However, in clinical
practice, coronary artery complications are often seen
even in KD patients with low CRP levels. In this study,
we aimed to assess the clinical features and occurrence
of coronary artery lesions (CAL) in patients with KD ac-
cording to serum CRP levels. In addition, we tried to
confirm whether CAL occurred in patients with low
serum CRP level before IVIG treatment.
Methods
This study was based on the 9th nationwide KD survey
performed under the guidance of the Korean Society of
KD in the Republic of Korea, which was conducted on
patients with KD who visited a hospital between January
2015 and December 2017. Data were collected using a
questionnaire regarding the clinical characteristics of pa-
tients, which were filled in by hospital medical staff. The
survey was approved by the Institutional Review Board
of our university hospital (no. H-1710-109-895, ap-
proved November 20, 2017).
The survey obtained data from 15,387 patients. Of
these patients, 6256 were excluded due to missing data
on serum CRP levels, coronary artery size, height, and
weight. Eventually, 9131 patients were enrolled in the
study and were divided into two groups according to
their serum CRP levels: low (< 3mg/dL) and high (≥ 3
mg/dL). We recorded serum CRP levels just before the
start of acute treatment. Coronary artery evaluation was
performed with echocardiography twice, during the
acute phase (maximal dilatation of the coronary arteries
after intravenous immunoglobulin [IVIG] treatment;
n = 9014) and post-convalescent period (approximately
8 weeks after disease onset; n = 8206).
The diagnosis of complete KD was based on the pres-
ence of four or more of the principal clinical criteria (ex-
tremity changes, rash, conjunctivitis, oral changes,
cervical lymphadenopathy), and patients with three or
fewer criteria and compatible laboratory or echocardio-
graphic findings were considered to have incomplete KD
[1]. Non-responsiveness to initial IVIG treatment was
defined as the requirement for the administration of
second-line treatment, such as a second dose of IVIG or
intravenous steroids.
The complications of KD were assessed based on the
development of CAL on the left main coronary artery.
The z-score was calculated using a previously reported
formula [6], and a z-score ≥ 2.5 was considered to be
CAL. We also assessed CAL development according to
the criteria of the Japanese Ministry of Health and Wel-
fare (Japanese criteria) [7, 8], which defined CAL as a
coronary artery diameter ≥ 3mm in children < 5 years
old and ≥ 4 mm in children ≥5 years old. A z-score ≥ 10.0
and diameter > 8 mm were considered to indicate a giant
coronary artery aneurysm (CAA).
Statistical analysis
Data were expressed as the mean ± standard deviation,
median (range), or percentage (%), as appropriate. We
compared the characteristics of patients, treatment, and
coronary artery complications between the low and high
CRP groups. An independent t-test was performed to
compare continuous variables, and a chi-squared test
was used to analyze categorical variables. We performed
logistic regression analysis to identify potential risk fac-
tors for the development of CAL. A p-value < 0.05 was
considered statistically significant. All statistical analyses
were conducted using IBM SPSS Statistics for Windows,
version 20 (IBM Corp., Armonk, NY, USA).
Results
The mean age at diagnosis was 33.7 ± 24.9 months, and
the proportion of male children was 58.1% (male:female
ratio, 1.41:1). The average duration of fever before treat-
ment was 5.1 ± 1.8 days, and the total fever duration was
6.5 ± 2.3 days. The mean serum CRP level in all children
was 7.4 ± 5.8 mg/dL. The low CRP group accounted for
23% of all KD patients.
Comparison of clinical characteristics by CRP level
The mean age at diagnosis was higher in the high CRP
group compared to the low CRP group (34.4 ± 24.9 vs
31.7 ± 24.8 months, p < 0.001) and total fever duration
was longer in the high CRP group than the low CRP
group (6.6 ± 2.2 vs 6.3 ± 2.5 days, p < 0.001). However,
pretreatment fever duration was not significantly differ-
ent between the two groups (high vs. low group, 5.1 ±
1.7 days vs. 5.2 ± 2.1 days; p = 0.206). The principal
symptoms, except for Bacillus Calmette–Guérin (BCG)
site redness, were all more frequently observed in the
high CRP group than in the low CRP group. An incom-
plete presentation of KD was more frequently observed
in the low CRP group than in the high CRP group (high
vs. low group, 31.7% vs. 42.1%, p < 0.001). White blood
cell count, percentage of neutrophil count, aspartate
aminotransferase, and alanine aminotransferase levels
were significantly higher in the high CRP group than in
the low CRP group (Table 1).
Treatment of KD
Overall, 341 (3.7%) patients were not given IVIG because
of spontaneous alleviation of fever. Such patients were
found more frequently in the low CRP group than in the
high CRP group (low vs. high groups, 174 (8.3%) patients
vs. 167 (2.4%) patients; p < 0.001). The first-line drug
treatment for acute KD was IVIG (2 g/kg), and 1602 pa-
tients were non-responsive to this treatment (18.3%).
An et al. Pediatric Rheumatology           (2021) 19:78 Page 2 of 7
The non-response rate was lower in the low CRP group
than in the high CRP group (225 [11.7%] patients vs.
1377 [20.1%] patients, respectively; p < 0.001). Among
patients who were non-responsive to initial IVIG, a sec-
ond IVIG dose was administered to 1435 patients
(89.6%). Among them, 342 patients were non-responsive
(23.8%), and there was no significant difference between
the two groups (high vs. low group, 302 [24.4%] patients
vs. 40 [20.2%] patients; p = 0.209; Table 2).
Coronary artery complications
In the acute phase, the overall prevalence of CAL was
14.1% based on the z-score and 10.5% based on the Japa-
nese criteria. After the convalescent period, the CAL
prevalence, according to the two criteria, decreased to
6.1 and 5.1%, respectively. A giant CAA was found in
0.6% (z-score) and 0.1% (Japanese criteria) of patients in
the acute phase and 0.3% (z-score) and 0.1% (Japanese
criteria) after the convalescent period (Fig. 1). A decline
Table 1 Clinical characteristics between patients with low and high C-reactive protein levels among patient with KD
Characteristics Total Low CRP < 3mg/dL High CRP ≥ 3mg/dL p-
valuen Value n Value
N (%) 9131 2107 23.1 7024 76.9
Age, months (mean ± SD) 9131 2107 31.7 ± 24.8 7024 34.4 ± 24.9 < 0.001
Male, n (%) 9053 2081 1261 (60.6) 6972 4042 (58.0) 0.033
Weight, kg (mean ± SD) 9131 2107 13.8 ± 6.0 7024 14.2 ± 5.9 0.003
Height, cm (mean ± SD) 9131 2107 90.2 ± 17.4 7024 92.2 ± 17.3 < 0.001
Fever, total days (mean ± SD) 8810 2027 6.3 ± 2.5 6783 6.6 ± 2.2 < 0.001
Fever, pretreatment, days (mean ± SD) 9025 2072 5.2 ± 2.1 6998 5.1 ± 1.7 0.206
Symptoms, n (%)
Conjunctival injection 9010 2054 1664 (81.0) 6956 6220 (89.4) < 0.001
Oral changes 9001 2050 1604 (78.2) 6951 5865 (84.4) < 0.001
Extremity changes 8918 2028 1247 (61.5) 6890 4651 (67.5) < 0.001
Rash 8984 2053 1484 (72.3) 6931 5349 (77.2) < 0.001
BCG site redness 8354 1914 769 (40.2) 6440 2520 (39.1) 0.424
Cervical lymphadenopathy 8960 2047 1015 (49.6) 6913 4179 (60.5) < 0.001
Incomplete presentation, n (%) 8914 2006 844 (42.1) 6908 2187 (31.7) < 0.001
Family history, n (%) 6543 1414 24 (1.7) 5129 68 (1.3) 0.312
Recurrence, n (%) 8781 2017 99 (4.9) 6763 337 (5.0) 0.953
Laboratory results
WBC, /mm3 (mean ± SD) 9126 2106 11.988 ± 4.881 7020 14.818 ± 5.163 < 0.001
Neutrophil, % (mean ± SD) 9037 2066 52.2 ± 16.9 6971 66.5 ± 14.6 < 0.001
Hemoglobin, g/dL (mean ± SD) 9096 2100 11.6 ± 0.97 6996 11.3 ± 1.02 < 0.001
Platelets, × 103 (mean ± SD) 9105 2103 357.4 ± 126.8 7002 356.5 ± 109.8 0.765
Platelets, ×10 [3], highest (mean ± SD) 8651 2002 422.6 ± 147.0 6649 483.6 ± 165.4 < 0.001
Albumin, g/dL (mean ± SD) 9093 2093 4.0 ± 0.3 7000 3.8 ± 0.4 < 0.001
AST, IU/L (mean ± SD) 9105 2100 64.6 ± 125.9 7005 94.0 ± 173.5 < 0.001
ALT, IU/L (mean ± SD) 9095 2096 59.8 ± 131.5 6999 100.1 ± 149.3 < 0.001
Total bilirubin, mg/dL (mean ± SD) 8978 2070 0.4 ± 0.47 6908 0.68 ± 0.83 < 0.001
Na, mEq/L (mean ± SD) 8983 2059 137.0 ± 2.4 6924 136.2 ± 2.7 < 0.001
CRP, mg/dL (mean ± SD) 9131 2107 1.59 ± 0.86 7024 9.20 ± 5.49 < 0.001
ESR, mm/hr. (mean ± SD)
8356
1919 41.5 ± 24.9 6437 60.7 ± 26.7 < 0.001
BNP, pg/mL (mean ± SD) 2079 519 55.3 ± 94.0 1559 199.4 ± 597.3 < 0.001
ProBNP, pg/mL (mean ± SD) 5533 1266 551.5 ± 1081.5 4267 1624.2 ± 3400.8 < 0.001
Pyuria, n (%) 9008 2076 409 (19.7) 6932 2652 (38.3) < 0.001
KD Kawasaki Disease, CRP C-reactive protein, BCG Bacillus Calmette–Guérin, WBC White blood cell, AST Aspartate aminotransferase, ALT Alanine aminotransferase,
BNP B-type natriuretic peptide, SD Standard deviation
An et al. Pediatric Rheumatology           (2021) 19:78 Page 3 of 7
in both the size and prevalence of CAL was found in the
post-convalescent period compared to the acute phase
of KD based on both criteria (z-score and Japanese cri-
teria; Fig. 2).
In this study, the occurrence of CAL was higher in in-
complete KD than complete KD. (Supplementary 3), and
these incomplete KD was higher in the low CRP group. In
the other hand, in an analysis performed only in incom-
plete KD patients, the occurrence of CAL was frequent in
low CRP group than the high CRP group. However in
complete KD patients, there was not difference of CAL by
CRP group. (Supplementary Table 4A, B).
Fever duration before treatment was one of the risk
factors for the development of acute CAL in the
Table 2 Response to treatment and coronary artery complications in children with Kawasaki disease
Outcomes Total
n (%)
Low CRP < 3mg/dL
(n = 2107), n (%)
High CRP ≥ 3mg/dL
(n = 7024), n (%)
p-value
Spontaneous remission 341 (3.7) 174 (8.3) 167 (2.4) < 0.001
1st IVIG 8778 (96.1) 1929 (91.6) 6849 (97.5) < 0.001
Unresponsive to 1st IVIG 1602/8778 (18.3) 225 (11.7) 1377 (20.1) < 0.001
2nd IVIG 1435/1602 (89.6) 198 (88.0) 1237 (89.8) 0.453
Unresponsive to 2nd IVIG 342/1435 (23.8) 40 (20.2) 302 (24.4) 0.209
Acute CAL
z-score 1271/9000 (14.1) 2082 380 (18.3) 6918 891 (12.9) < 0.001
Japanese criteria 946/9014 (10.5) 2084 260 (12.5) 6930 686 (9.9) 0.001
Acute giant CAA
z-score 56/9014 (0.6) 2084 13 (0.6) 6930 43 (0.6) 1.0
Japanese criteria 13/9110 (0.1) 2101 3 (0.1) 7009 10 (0.1) 1.0
Convalescent CAL
z-score 501/8196 (6.1) 1873 160 (8.5) 6323 341 (5.4) < 0.001
Japanese criteria 419/8203 (5.1) 1875 127 (6.8) 6328 292 (4.6) < 0.001
Convalescent giant CAA
z-score 28/8204 (0.3) 1875 1 (0.1) 6329 27 (0.4) 0.011
Japanese criteria 8/8661 (0.1) 1971 0 6690 8 (0.1) 0.212
KD Kawasaki Disease, CRP C-reactive protein, IVIG Intravenous immunoglobulin treatment, CAL Coronary artery lesion, CAA Coronary artery aneurysm; Japanese
criteria, criteria of the Japanese Ministry of Ministry of Health and Welfare
Fig. 1 Incidence of coronary artery lesions in Korean children with Kawasaki disease based on the z-score [6]. A Acute phase and B convalescent
phase. CAL; coronary artery lesion, CAA; coronary artery aneurysm, CRP; C-reactive protein
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multivariable analysis. Regardless of the serum CRP
level, if the duration of fever was longer, the risk of CAL
was higher (odds ratio [OR], 1.112 [1.064–1.163]; p <
0.001). Furthermore, IVIG non-responsiveness was asso-
ciated with CAL development (OR, 2.617 [2.064–3.317];
p < 0.001).
In the high CRP group, the acute CAL risk was higher
among non-responders to the second IVIG dose than
among non-responders to the first IVIG dose (initial
IVIG response: OR, 1.414 [1.223–1.634], p < 0.001; sec-
ond IVIG response: OR, 2.884 [2.234–3.723], p < 0.001).
In the low CRP group, responsiveness to initial IVIG
treatment was not associated with CAL occurrence. In-
creased CAL risk was shown only for non-responders to
the second IVIG dose (initial IVIG response: OR, 1.147
[0.811–1.623], p = 0.438; second IVIG response: OR,
2.283 [1.162–4.486], p < 0.017).
We performed a risk factor analysis for acute CAL de-
velopment in the low CRP group. In the univariable
analysis, the age at diagnosis, incomplete presentation of
KD, fever duration before treatment, and non-
responsiveness to secondary IVIG showed a statistically
significant result (all p < 0.05). In the multivariable ana-
lysis, all of these factors were also a risk factor for the
occurrence of CAL (Table 3).
Discussion
In this retrospective analysis of the 9th Korean nation-
wide survey of KD, the development of CAL was also
found in patients with low serum CRP levels. In the low
CRP group, CAL was observed in 18.3 and 12.5% of pa-
tients during the acute phase and 8.5 and 6.8% of pa-
tients after the convalescent period based on the z-score
and Japanese criteria, respectively.
CAL occurrence was higher in the low CRP group
than in the high CRP group. Our study design did not
allow us to identify or define the cause of this observa-
tion. However, patients in the low CRP group were
younger at KD diagnosis and more often presented with
incomplete KD, which may be associated with a higher
CAL occurrence than in patients in the high CRP group
[1, 9, 10]. In analysis of incomplete KD, the occurrence
of CAL was higher in low CRP group than that in high
CRP group, but this pattern was not prominent in
Fig. 2 Coronary artery lesion assessment during the acute and convalescence stages in Korean children with Kawasaki disease. A decline in both
the size and prevalence of coronary artery lesions in the left main coronary artery during the post-convalescent period was observed compared
to the acute phase using both evaluation methods (z-score (A) and Japanese criteria [7, 8] (B)). CRP; C-reactive protein, CAL; coronary artery lesion
Table 3 Risk factors for coronary artery lesion in patients with low C-reactive protein
Univariable analysis Multivariable analysis
OR (95% CI) p-value OR (95% CI) p-value
Age at diagnosis 0.953 (0.901, 1.008) 0.090 0.930 (0.873, 0.991) 0.025
Incomplete KD 2.188 (1.713, 2.794) < 0.001 2.142 (1.672, 2.745) < 0.001
Fever, pretreatment 1.092 (1.041, 1.145) < 0.001 1.101 (1.045, 1.159) < 0.001
2nd IVIG unresponsiveness 2.283 (1.162, 4.486) 0.017 3.235 (1.550, 6.753) 0.014
During acute phase of KD
KD Kawasaki Disease, OR Odds ratio, IVIG Intravenous immunoglobulin, BCG Bacillus Calmette–Guérin
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analysis of complete KD. Therefore, it should be noted
that CAL may occur even in incomplete patients with
low CRP.
Although we did not describe it above, the patients
have been also evaluated by ESR level (low ESR < 40
mm/hr. ≤ high ESR) (supplementary Table 1). As the re-
sult of CRP, it was confirmed that CAL occurred even in
the low ESR group. In other words, it was confirmed
that CAL also occurred in patients with low initial in-
flammatory maker level.
In general, the risk assessment of coronary artery compli-
cations is evaluated based on IVIG responsiveness, and high
serum CRP levels are regarded as a related factor for the
non-responsiveness to IVIG [11, 12]. The CRP value used
to predict this non-responsiveness to IVIG is the initial
CRP level, which reflects the inflammatory state prior to
IVIG treatment. However, the initial serum CRP level alone
may not be sufficient to predict complications. Nandi et al.
showed a difference in the CRP and interleukin-6 (IL-6; a
cytokine that stimulates inflammatory markers, including
CRP) levels between IVIG responders and non-responders.
They found that CRP and IL-6 levels were higher after
IVIG treatment in IVIG non-responders than in re-
sponders; however, these levels were not significantly differ-
ent before IVIG treatment [5]. High CRP levels after initial
IVIG were also reported to be a risk factor for non-
responsiveness to additional IVIG treatment in refractory
KD patients [13, 14]. Because the serum CRP levels after
IVIG treatment were not investigated in this study, it is dif-
ficult to draw definitive conclusions, but we believe that the
serum CRP level before IVIG treatment is insufficient to
predict coronary artery complications.
In our study, the fever duration before treatment was
not different between the low and high CRP groups, but
there was a difference in responsiveness to IVIG treat-
ment. In patients with low serum CRP levels, the rate of
non-responsiveness to the first IVIG dose was 11.7%,
which was considerably lower than the overall nonre-
sponse rate (18.3%) to the first IVIG dose among all pa-
tients. In patients with low serum CRP levels, the response
rate to the first IVIG dose was good, but coronary artery
complications still occurred in some of these patients,
which suggest that patients with low CRP levels may not
be a homogeneous group. Some patients responded well
to treatment without coronary complications, as would be
expected based on their low CRP serum levels in others,
coronary complications were found although they had ap-
propriate treatment. One may hypothesize that a rise in
CRP levels occurred after the initial test, but further re-
search is required to test such a hypothesis.
In both groups, the presence of some principle symp-
toms was associated with a low risk of CAL. Notably, in
the low CRP group, the presence of BCG site redness
showed a low risk of CAL. Similar trends were identified
in the high CRP group, with the presence of principle
symptoms associated with a low risk of CAL. These re-
sults are in line with the findings of a previous study,
which showed that coronary artery complications may
be high due to the delayed diagnosis and treatment of
patients with incomplete KD who have insufficient clin-
ical symptoms to match the diagnostic criteria [1].
In this study, the characteristics of patients were simi-
lar to those of patients in the nationwide survey and
other reported data [15–17]. However, our results
should be interpreted within the limitations of this
study. Because this analysis was performed retrospect-
ively, patients lacking essential data required to interpret
the results of this study were excluded (n = 6256); thus,
9131 patients who met the inclusion criteria were ana-
lyzed. Furthermore, serum CRP levels were collected just
prior to initial IVIG treatment, but the exact day of sam-
pling from fever onset was not investigated. The serum
CRP level was associated with KD disease duration and
it could not be linked with coronary artery outcome dir-
ectly. In addition, since CRP after IVIG treatment has
not been investigated, we cannot make any conclusions
about the occurrence of CALs following CRP changes.
Conclusions
Coronary artery complications in KD occurred not only
with high serum CRP levels (≥3mg/dL) but also low
serum CRP levels (< 3mg/dL) of before IVIG treatment.
In addition, the CAL occurrence rate was higher in pa-
tients with low serum CRP levels than in patients with
high serum CRP levels, which was associated with the
higher CAL occurrence rate in incomplete KD. Therefore,
we recommend monitoring the clinical course of KD care-
fully, regardless of the serum CRP level, and to note that
coronary artery complications are not predictable based
on serum CRP levels prior to IVIG treatment alone.
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